Fortuna Fix: paradigm-shifting autologous cell therapies for neurodegenerative diseases

“Fortuna’s industry-leading automated autologous cell manufacturing platform offers a significant competitive advantage, allowing highly reliable and reproducible production of therapeutically relevant transplantable cells,” said Philip Tagari, VP of research at Amgen. “Once fully developed, their analytical technology and comprehensive final product characterization could help to enable efficient and definitive clinical development in a variety of neurological diseases.”

Read More
CompanyMasha Stromme